GlassScriptPhysician profile
Nauman Tahir
NPI 1962633057
$3,402.86
in general payments reported to CMS, 2019-2025
17 companies · $2,219 in 2025
The $2,219 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.33 · 2021: $35.53 · 2022: $720 · 2023: $186 · 2024: $183 · 2025: $2,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,800 · Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,800.00 |
| Food and Beverage | $787.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $1,872.54 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $292.13 | 2020-2024 | Lokelma |
| Glaxosmithkline, LLC. | $240.21 | 2022-2023 | Benlysta |
| Vifor Pharma, INC. | $166.98 | 2022 | |
| Mallinckrodt Hospital Products INC. | $129.28 | 2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $126.71 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $110.77 | 2022-2024 | Jynarque |
| Nxstage Medical, INC. | $98.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2022 | |
| Aurinia Pharma U.S., INC. | $53.68 | 2024-2025 | Lupkynis |
| Novo Nordisk INC | $51.00 | 2023-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $47.59 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.87 | 2024-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $31.79 | 2024 | Velphoro |
| Travere Therapeutics, INC. | $20.56 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.11 | 2024 | |
| Ibsa Pharma INC. | $16.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nauman Tahir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.